INTEGRA LIFESCIENCES HOLDINGS CORP Revenue
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Revenue of $418.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-29
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $418.76M, a 0.76% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $391.92M, a 2.42% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $434.93M, a 1.74% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $402.06M, a 5.57% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.64B, a 1.53% increase from fiscal 2024.
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.61B, a 4.47% increase from fiscal 2023.
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.54B, a 1.03% decline from fiscal 2022.
- INTEGRA LIFESCIENCES HOLDINGS CORP revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.56B, a 0.99% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $418.76M 10-Q · filed 2026-07-29 | $810.68M 10-Q · filed 2026-07-29 | $1.25B derived: sum of 3 quarters · filed 2026-07-29 | $1.65B derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $391.92M 10-Q · filed 2026-05-05 | $826.84M derived: sum of 2 quarters · filed 2026-05-05 | $1.23B derived: sum of 3 quarters · filed 2026-05-05 | $1.64B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $434.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $836.99M derived: sum of 2 quarters · filed 2026-02-26 | $1.25B derived: sum of 3 quarters · filed 2026-07-29 | $1.64B 10-K · filed 2026-02-26 |
| 2025-09-30 | $402.06M 10-Q · filed 2025-10-30 | $817.67M derived: sum of 2 quarters · filed 2026-07-29 | $1.20B 10-Q · filed 2025-10-30 | $1.64B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $415.61M 10-Q · filed 2026-07-29 | $798.26M 10-Q · filed 2026-07-29 | $1.24B derived: sum of 3 quarters · filed 2026-07-29 | $1.62B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $382.65M 10-Q · filed 2026-05-05 | $825.30M derived: sum of 2 quarters · filed 2026-05-05 | $1.21B derived: sum of 3 quarters · filed 2026-05-05 | $1.62B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $442.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $823.48M derived: sum of 2 quarters · filed 2026-02-26 | $1.24B derived: sum of 3 quarters · filed 2026-02-26 | $1.61B 10-K · filed 2026-02-26 |
| 2024-09-30 | $380.83M 10-Q · filed 2025-10-30 | $799.01M derived: sum of 2 quarters · filed 2025-10-30 | $1.17B 10-Q · filed 2025-10-30 | $1.56B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $418.18M 10-Q · filed 2025-07-31 | $787.05M 10-Q · filed 2025-07-31 | $1.18B derived: sum of 3 quarters · filed 2026-02-26 | $1.57B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $368.87M 10-Q · filed 2025-05-05 | $765.91M derived: sum of 2 quarters · filed 2026-02-26 | $1.15B derived: sum of 3 quarters · filed 2026-02-26 | $1.53B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $397.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $779.46M derived: sum of 2 quarters · filed 2026-02-26 | $1.16B derived: sum of 3 quarters · filed 2026-02-26 | $1.54B 10-K · filed 2026-02-26 |
| 2023-09-30 | $382.42M 10-Q · filed 2024-11-04 | $763.69M derived: sum of 2 quarters · filed 2024-11-04 | $1.14B 10-Q · filed 2024-11-04 | $1.54B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $381.27M 10-Q · filed 2024-07-29 | $762.11M 10-Q · filed 2024-07-29 | $1.16B derived: sum of 3 quarters · filed 2025-02-25 | $1.55B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $380.85M 10-Q · filed 2024-05-06 | $778.87M derived: sum of 2 quarters · filed 2025-02-25 | $1.16B derived: sum of 3 quarters · filed 2025-02-25 | $1.56B derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $398.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $783.21M derived: sum of 2 quarters · filed 2025-02-25 | $1.18B derived: sum of 3 quarters · filed 2025-02-25 | $1.56B 10-K · filed 2025-02-25 |
| 2022-09-30 | $385.19M 10-Q · filed 2023-10-25 | $783.01M derived: sum of 2 quarters · filed 2023-10-25 | $1.16B 10-Q · filed 2023-10-25 | $1.57B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $397.81M 10-Q · filed 2023-07-27 | $774.45M 10-Q · filed 2023-07-27 | $1.18B derived: sum of 3 quarters · filed 2024-02-28 | $1.57B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $376.64M 10-Q · filed 2023-04-26 | $782.16M derived: sum of 2 quarters · filed 2024-02-28 | $1.17B derived: sum of 3 quarters · filed 2024-02-28 | $1.56B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $405.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $792.38M derived: sum of 2 quarters · filed 2024-02-28 | $1.18B derived: sum of 3 quarters · filed 2024-02-28 | $1.54B 10-K · filed 2024-02-28 |
| 2021-09-30 | $386.86M 10-Q · filed 2022-10-26 | $776.85M derived: sum of 2 quarters · filed 2022-10-26 | $1.14B 10-Q · filed 2022-10-26 | $1.53B derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | $389.99M 10-Q · filed 2022-07-27 | $750.06M 10-Q · filed 2022-07-27 | $1.14B derived: sum of 3 quarters · filed 2022-07-27 | $1.51B derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | $360.07M 10-Q · filed 2022-04-27 | $748.72M derived: sum of 2 quarters · filed 2022-04-27 | $1.12B derived: sum of 3 quarters · filed 2022-04-27 | $1.38B derived: sum of 4 quarters · filed 2022-04-27 |
| 2020-12-31 | $388.65M 10-K · filed 2021-02-23 | $758.88M derived: sum of 2 quarters · filed 2021-11-02 | $1.02B derived: sum of 3 quarters · filed 2021-11-02 | $1.37B 10-K · filed 2023-02-22 |
| 2020-09-30 | $370.23M 10-Q · filed 2021-11-02 | $628.90M derived: sum of 2 quarters · filed 2021-11-02 | $983.22M 10-Q · filed 2021-11-02 | $1.38B derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $258.67M 10-Q · filed 2021-07-29 | $612.99M 10-Q · filed 2021-07-29 | $1.01B derived: sum of 3 quarters · filed 2021-07-29 | $1.39B derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $354.32M 10-Q · filed 2021-04-29 | $749.45M derived: sum of 2 quarters · filed 2021-04-29 | $1.13B derived: sum of 3 quarters · filed 2021-04-29 | $1.51B derived: sum of 4 quarters · filed 2021-04-29 |
| 2019-12-31 | $395.13M 10-K · filed 2021-02-23 | $774.22M derived: sum of 2 quarters · filed 2021-02-23 | $1.16B derived: sum of 3 quarters · filed 2021-02-23 | $1.52B 10-K · filed 2022-02-24 |
| 2019-09-30 | $379.10M 10-K · filed 2021-02-23 | $762.74M derived: sum of 2 quarters · filed 2021-02-23 | $1.12B 10-Q · filed 2020-10-29 | $1.51B derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $383.64M 10-K · filed 2021-02-23 | $743.34M 10-Q · filed 2020-08-10 | $1.13B derived: sum of 3 quarters · filed 2021-02-23 | $1.49B derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $359.69M 10-K · filed 2021-02-23 | $743.00M derived: sum of 2 quarters · filed 2021-02-23 | $1.11B derived: sum of 3 quarters · filed 2021-02-23 | $1.48B derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $383.31M 10-K · filed 2020-02-21 | $749.17M derived: sum of 2 quarters · filed 2020-02-21 | $1.12B derived: sum of 3 quarters · filed 2020-02-21 | $1.47B 10-K · filed 2021-02-23 |
| 2018-09-30 | $365.85M 10-K · filed 2020-02-21 | $732.04M derived: sum of 2 quarters · filed 2020-02-21 | $1.09B 10-Q · filed 2019-10-25 | $1.46B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $366.19M 10-K · filed 2020-02-21 | $723.27M 10-Q · filed 2019-07-25 | $1.09B derived: sum of 3 quarters · filed 2020-02-21 | $1.37B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $357.08M 10-K · filed 2020-02-21 | $725.68M derived: sum of 2 quarters · filed 2020-02-21 | $1.00B derived: sum of 3 quarters · filed 2020-02-21 | $1.29B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $368.60M 10-K · filed 2019-02-26 | $647.44M derived: sum of 2 quarters · filed 2019-02-26 | $929.60M derived: sum of 3 quarters · filed 2019-02-26 | $1.19B 10-K · filed 2020-02-21 |
| 2017-09-30 | $278.83M 10-K · filed 2019-02-26 | $561.00M derived: sum of 2 quarters · filed 2019-02-26 | $819.63M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $282.16M 10-K · filed 2019-02-26 | $540.80M 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $258.64M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $992.08M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |